Assignee
PREC BIOSCIENCES INC
US·48 granted patents·93 pending applications·411 citations·filing 2010–2025
Top patents by PatentIndex Score
141 records- 0199US10041053B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2016·Granted Aug 7, 2018·43 cites·11 claims
- 0299US9434931B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2015·Granted Sep 6, 2016·63 cites·4 claims
- 0399US9340777B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2015·Granted May 17, 2016·49 cites·8 claims
- 0498US10851358B2Engineered meganucleases specific for recognition sequences in the hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2020·Granted Dec 1, 2020·11 cites·13 claims
- 0598US9889161B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·27 cites·4 claims
- 0698US9889160B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·65 cites·9 claims
- 0797US10093900B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·15 cites·9 claims
- 0897US9993501B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·11 cites·13 claims
- 0997US9993502B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·16 cites·13 claims
- 1097US9969975B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted May 15, 2018·13 cites·9 claims
- 1197US9950010B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 1297US9950011B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 1395US10800833B2Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2019·Granted Oct 13, 2020·7 cites·23 claims
- 1495US9683257B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2014·Granted Jun 20, 2017·10 cites·10 claims
- 1594US10287626B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2017·Granted May 14, 2019·5 cites·11 claims
- 1694US10093899B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·8 cites·9 claims
- 1793US11274285B2Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2020·Granted Mar 15, 2022·2 cites·18 claims
- 1893US10799535B2Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2016·Granted Oct 13, 2020·5 cites·5 claims
- 1993US10662416B2Engineered meganucleases specific for recognition sequences in the hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2017·Granted May 26, 2020·4 cites·9 claims
- 2093US10273524B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2017·Granted Apr 30, 2019·5 cites·11 claims
- 2191US11384335B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Jul 12, 2022·1 cites·3 claims
- 2291US11142750B2Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2019·Granted Oct 12, 2021·3 cites·6 claims
- 2391US11053484B2Genetically-modified T cells comprising a modified intron in the T cell receptor alpha genePREC BIOSCIENCES INC·Filed 2018·Granted Jul 6, 2021·5 cites·10 claims
- 2491US10603363B2Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·3 cites·10 claims
- 2591US2025121039A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2690US11680254B2Engineered meganucleases specific for recognition sequences in the PCSK9 genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 20, 2023·3 cites·8 claims
- 2790US11453861B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Sep 27, 2022·1 cites·8 claims
- 2890US11008548B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2020·Granted May 18, 2021·2 cites·3 claims
- 2989US12351839B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2023·Granted Jul 8, 2025·0 cites·11 claims
- 3089US11186822B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Nov 30, 2021·1 cites·3 claims
- 3187US9822381B2Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2015·Granted Nov 21, 2017·2 cites·11 claims
- 3287US2024401110A1Recognition sequences for i-crei-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3387US2024002796A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3487US2025082735A1Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleasesPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3587US2024238387A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3686US2024271111A1Engineered meganucleases specific for recognition sequences in the hepatitis b virus genomePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3786US2024156919A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3885US11286291B2Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2017·Granted Mar 29, 2022·2 cites·28 claims
- 3985US2025154481A1Engineered meganucleases specific for recognition sequences in the pcsk9 genePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4085US2024382526A1Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4184US2024084252A1Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)PREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4284US2023088311A1Recognition sequences for i-crei-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4384US2024035011A1Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genomePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4482US2024018215A1Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4582US2022135945A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4682US2022145251A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4781US12006522B2Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin genePREC BIOSCIENCES INC·Filed 2023·Granted Jun 11, 2024·0 cites·16 claims
- 4881US11993793B2Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin genePREC BIOSCIENCES INC·Filed 2023·Granted May 28, 2024·0 cites·16 claims
- 4981US11851680B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Dec 26, 2023·0 cites·3 claims
- 5081US2024101985A1Engineered meganucleases specific for recognition sequences in the pcsk9 genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 141 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PREC BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →